文献速递乳腺癌放疗胸部肿瘤放疗

乳腺癌放疗后左前降支剂量与心脏事件相关

Dose to the Left Anterior Descending Artery Correlates With Cardiac Events After Irradiation for Breast Cancer.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2022-04-25

该研究纳入2012至2018年375例连续接受左侧乳腺或胸壁放疗的女性患者,中位随访48个月,36例发生心脏事件、23例发生主要心脏事件。单因素和多因素分析显示左前降支平均剂量、最大剂量及心脏平均剂量升高与任何心脏事件和主要心脏事件风险增加相关。ROC曲线确定左前降支平均剂量EQD2阈值2.8 Gy,高于此值任何心脏事件风险更高(P=.001)。

要点

  • 左前降支平均剂量、最大剂量及心脏平均剂量升高与任何心脏事件和主要心脏事件风险增加相关。
  • 左前降支平均剂量EQD2阈值2.8 Gy以上任何心脏事件风险更高(P=.001)。
  • 作者认为左侧乳腺癌放疗患者应考虑勾画左前降支并尽量减少其剂量。

核心结论

  • 在该队列中,左前降支剂量与不良心脏事件相关。
  • 作者认为,对接受左侧乳腺癌放疗的患者,应考虑勾画左前降支并尽量减少其剂量。

研究设计与样本

  • 研究纳入2012年至2018年375例连续接受左侧乳腺或胸壁放疗(伴或不伴区域淋巴结放疗)的女性患者。
  • 查询病历以识别放疗后的心脏事件,计算左前降支平均剂量、左前降支最大剂量、心脏平均剂量和心脏最大剂量并转换为2 Gy等效剂量(EQD2)。
  • 采用单因素和多因素Cox回归分析确定与心脏毒性的关联,通过受试者工作特征(ROC)曲线分析确定4个剂量参数的潜在剂量阈值,再基于这些约束行Kaplan-Meier分析比较无心脏事件生存。

主要发现

  • 中位随访时间为48个月,36例患者发生心脏事件,23例患者发生主要心脏事件。
  • 单因素和多因素分析显示,左前降支平均剂量、左前降支最大剂量和心脏平均剂量升高与任何心脏事件和主要心脏事件风险增加相关。
  • ROC曲线分析确定左前降支平均剂量EQD2阈值为2.8 Gy(ROC曲线下面积0.69),高于此阈值任何心脏事件风险更高(P=.001)。
  • 按左前降支最大剂量EQD2阈值6.7 Gy分层(P=.005)和心脏平均剂量EQD2阈值0.8 Gy分层(P=.01)时也观察到类似结果。

关键数值与推荐

  • 左前降支平均剂量EQD2阈值为2.8 Gy(ROC曲线下面积0.69),高于此值任何心脏事件风险更高(P=.001)。
  • 左前降支最大剂量EQD2阈值为6.7 Gy(P=.005)。
  • 心脏平均剂量EQD2阈值为0.8 Gy(P=.01)。

临床怎么用

  • 作者认为,对接受左侧乳腺癌放疗的患者,应考虑勾画左前降支并尽量减少其剂量。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Although global heart dose has been associated with late cardiac toxic effects in patients who received radiation therapy for breast cancer, data detailing the clinical significance of cardiac substructure dosimetry are limited. We investigated whether dose to the left anterior descending artery (LAD) correlates with adverse cardiac events. METHODS AND MATERIALS: We identified 375 consecutively treated female patients from 2012 to 2018 who received left-sided breast or chest wall irradiation (with or without regional nodal irradiation). Medical records were queried to identify cardiac events after radiation therapy. Mean and maximum LAD and heart doses (LAD Dmean, LAD Dmax, heart Dmean, and heart Dmax) were calculated and converted to 2-Gy equivalent doses (EQD2). Univariate and multivariable Cox regression analyses were performed to determine association with cardiac toxic effects. Potential dose thresholds for each of the 4 dose parameters were identified by receiver operating characteristic (ROC) curve analysis, after which Kaplan-Meier analysis was performed to compare cardiac event-free survival based on these constraints. RESULTS: Median follow-up time was 48 months. Thirty-six patients experienced a cardiac event, and 23 patients experienced a major cardiac event. On univariate and multivariable analyses, increased LAD Dmean, LAD Dmax, and heart Dmean were associated with increased risk of any cardiac event and a major cardiac event. ROC curve analysis identified a threshold LAD Dmean EQD2 of 2.8 Gy (area under the ROC curve, 0.69), above which the risk for any cardiac event was higher (P = .001). Similar results were seen when stratifying by LAD Dmax EQD2 of 6.7 Gy (P = .005) and heart Dmean EQD2 of 0.8 Gy (P = .01). CONCLUSIONS: Dose to the LAD correlated with adverse cardiac events in this cohort. Contouring and minimizing dose to the LAD should be considered for patients receiving radiation therapy for left-sided breast cancer.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Zureick AH, Grzywacz VP, Almahariq MF, et al. Dose to the Left Anterior Descending Artery Correlates With Cardiac Events After Irradiation for Breast Cancer. Int J Radiat Oncol Biol Phys. 2022. PMID: 35483540. doi:10.1016/j.ijrobp.2022.04.019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。